Literature DB >> 11572639

Study of the correlation between administered activity and radiation committed dose to the thyroid in 131I therapy of Graves' disease.

A C Traino1, F Di Martino, M Lazzeri, M G Stabin.   

Abstract

Substantial reduction in the thyroid volume (up to 70-80%) after 131I therapy of Graves' disease has been demonstrated and reported in the literature. Recently a mathematical model of thyroid mass reduction during the first month after therapy has been developed and a new algorithm for the radiation committed dose calculation has been proposed. Reduction of the thyroid mass and the radiation committed dose to the gland depend on a parameter k, defined for each subject. The calculation of k allows the prediction of the activity to administer, depending on the radiation committed dose chosen by the physician. In this paper a method for calculating k is proposed. The calculated values of k are compared to values derived from measurements of the changes in thyroid mass in twenty-six patients treated by 131I for Graves' disease. The radiation committed dose to the thyroid can be predicted within 21%, and the radioiodine activity to administer to the patient can be predicted within 22% using the calculated values of k. The thyroid volume reduction during the first month after therapy administration can be also predicted with good accuracy using the calculated values of k. The radiation committed dose and the radioiodine activity to administer were calculated using a new, very simple algorithm. A comparison between the values calculated by this new algorithm and the old, classical Marinelli-Quimby algorithm shows that the new method is more accurate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572639     DOI: 10.1093/oxfordjournals.rpd.a006531

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  5 in total

1.  Clinical efficacy of radioiodine therapy in multinodular toxic goiter, applying an implemented dose calculation algorithm.

Authors:  Mara Schiavo; Maria Claudia Bagnara; Laura Camerieri; Elena Pomposelli; Massimo Giusti; Giampaola Pesce; Cristina Reitano; Mauro Caputo; Marcello Bagnasco
Journal:  Endocrine       Date:  2014-08-24       Impact factor: 3.633

2.  A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid.

Authors:  M Schiavo; M C Bagnara; I Calamia; I Bossert; E Ceresola; F Massaro; M Giusti; A Pilot; G Pesce; M Caputo; M Bagnasco
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

3.  The route of administration (oral vs intravenous) does not influence dose or outcome in Graves' disease and unifocal autonomy.

Authors:  Peter Schneider; Johannes Biko; Heribert Hänscheid; Stephan Hilliger; Christos Koutsampelas; Michael Kranzfelder; Stephan Ladner; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-10       Impact factor: 9.236

4.  Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (99mTc) scintigraphy.

Authors:  Piotr Szumowski; Małgorzata Mojsak; Saeid Abdelrazek; Monika Sykała; Anna Amelian-Fiłonowicz; Dorota Jurgilewicz; Janusz Myśliwiec
Journal:  Endocrine       Date:  2016-08-24       Impact factor: 3.633

5.  The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation.

Authors:  Muthiah Subramanian; Manu Kurian Baby; Krishna G Seshadri
Journal:  Endocr Connect       Date:  2016-01-15       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.